Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) will issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The business had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Voyager Therapeutics Price Performance

NASDAQ:VYGR traded up $0.63 during mid-day trading on Wednesday, hitting $7.28. 762,398 shares of the company's stock were exchanged, compared to its average volume of 645,060. Voyager Therapeutics has a one year low of $5.71 and a one year high of $11.72. The business has a fifty day moving average price of $6.56 and a 200 day moving average price of $7.55. The company has a market cap of $396.98 million, a PE ratio of 23.75 and a beta of 0.89.

Insider Transactions at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares of the company's stock, valued at $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.53% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on VYGR. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, October 24th. Leerink Partnrs raised shares of Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price objective on the stock. Wedbush dropped their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of "Buy" and a consensus price target of $17.43.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.